非アルコール性脂肪性肝炎（NASH）の世界市場レポート 2024

非アルコール性脂肪性肝炎（NASH）の市場規模は、今後数年間で急激に成長すると予想されています。 2028年には33.7%の年間複合成長率（CAGR）で145億3,000万米ドルに成長すると予想されます。予測期間で予想される成長は、NASH治療薬開発の進歩、スクリーニングへの取り組みの増加、ヘルスケア支出の増加、共同調査、および政府の支援によって推進されます。主な動向には、ライフスタイルへの介入、臨床調査におけるコラボレーションの強化、規制の進歩、診断とモニタリングにおける人工知能の統合への注目が含まれます。

肥満の蔓延により、非アルコール性脂肪性肝炎（NASH）市場の需要が高まっています。異常または過剰な脂肪の蓄積を特徴とする肥満は、健康上の重大な懸念を引き起こし、所定の身長の人にとって健康なレベルまたは標準レベルを超える体重を表します。肥満のパンデミックによって非アルコール性脂肪肝疾患の発生率が増加しているため、NASHは今後数十年間で重篤な肝疾患の潜在的な主な原因となる可能性があります。このリスクの高まりは、NASH治療および関連医薬品の必要性が高まっていることを浮き彫りにしています。 2021年4月に世界肥満連盟が発行した「COVID-19と肥満、2021年アトラス」で報告されているように、米国人口の60％以上が過体重と記録されています。さらに、レポートは、2025年までに米国人口の肥満率が男性で44.2%、女性で44.4%に増加すると予測しています。このデータは、肥満症例の憂慮すべき増加を浮き彫りにしており、肥満蔓延の結果として非アルコール性脂肪性肝炎（NASH）市場の予想成長軌道を補強しています。

高齢者人口の増加は、非アルコール性脂肪性肝炎（NASH）市場の需要を促進する主な要因です。 65歳以上の個人を表す高齢者人口は、加齢に伴う特定のヘルスケアニーズを示します。 NASH市場内で進行中の治療法の開発と進歩は、高齢者の全体的な健康状態を向上させ、高齢者に蔓延する肝臓関連疾患に対処する上で重要な役割を果たしています。 2022年 10月に世界保健機関が示したように、世界の高齢者人口は大幅に増加し、2030年までに6人に1人が60歳以上となり、2050年までに推定21億人の高齢者になると予想されています。この人口動態の変化は、非アルコール性脂肪性肝炎（NASH）市場の成長を促進する上で、高齢者人口の増加が重要な役割を担っていることを裏付けています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界の非アルコール性脂肪性肝炎（NASH）市場、タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 固体
• 液体
• 世界の非アルコール性脂肪性肝炎（NASH）市場、製品別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• ビタミンEとピオグリタゾン
• オカリバ
• エラフィブラノール
• セロンセルチブとセニクリビロック
• その他の製品
• 世界の非アルコール性脂肪性肝炎（NASH）市場、疾患原因別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 高血圧
• 心臓病
• 高血中脂質
• 2型糖尿病
• 肥満
• 世界の非アルコール性脂肪性肝炎（NASH）市場、販売チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院薬局
• 小売薬局
• オンラインプロバイダー
• 世界の非アルコール性脂肪性肝炎（NASH）市場、用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 経口
• 非経口

第7章 地域および国の分析

• 世界の非アルコール性脂肪性肝炎（NASH）市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界の非アルコール性脂肪性肝炎（NASH）市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 非アルコール性脂肪性肝炎（NASH）市場の競合情勢
• 非アルコール性脂肪性肝炎（NASH）市場企業プロファイル
  • NGM Biopharmaceuticals Inc.
  • Novartis AG
  • AstraZeneca plc.
  • GlaxoSmithKline plc.
  • F. Hoffmann-La Roche AG

第31章 その他の主要および革新的な企業

• The Takeda Pharmaceutical Company Limited
• Gilead Sciences Inc.
• Novo Nordisk A/S
• Genfit SA
• Cadila Pharmaceuticals Ltd.
• Intercept Pharmaceuticals Inc.
• Enanta Pharmaceuticals Inc.
• Blade Therapeutics Inc.
• Cempra Pharmaceuticals Inc.
• Galmed Pharmaceuticals Inc.
• Immuron Limited
• Terns Pharmaceuticals Inc.
• Tobira Therapeutics Inc.
• Arena Pharmaceuticals Inc.
• Vivus LLC

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

Non-alcoholic steatohepatitis (NASH) represents an advanced stage of fatty liver disease, distinguished by inflammation of the liver, and has the potential to progress to cirrhosis and liver failure.

Non-alcoholic steatohepatitis (NASH) is classified into solid and liquid forms. Solid variants are predominantly produced in crystalline forms, sold in tablet formats for oral consumption, owing to their superior purity and durability. Products in this category, such as vitamin E, pioglitazone, ocaliva, elafibranor, selonsertib, cenicriviroc, and others, target various health conditions including hypertension, heart disease, high blood lipid, type 2 diabetes, and obesity. These products are distributed through hospital pharmacies, retail pharmacies, and online providers, encompassing both oral and parenteral applications.

The non-alcoholic steatohepatitis (NASH) market research report is one of a series of new reports from The Business Research Company that provides non-alcoholic steatohepatitis (NASH) market statistics, including non-alcoholic steatohepatitis (NASH) industry global market size, regional shares, competitors with non-alcoholic steatohepatitis (NASH) market share, detailed non-alcoholic steatohepatitis (NASH) market segments, market trends, and opportunities, and any further data you may need to thrive in the non-alcoholic steatohepatitis (NASH) industry. This non-alcoholic steatohepatitis (NASH) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The non-alcoholic steatohepatitis (nash) market size has grown exponentially in recent years. It will grow from $3.33 billion in 2023 to $4.54 billion in 2024 at a compound annual growth rate (CAGR) of 36.3%. The expansion observed in the previous period can be ascribed to the increasing incidence of non-alcoholic steatohepatitis (NASH), the surge in obesity rates, heightened awareness and diagnostic efforts, changes in lifestyle and dietary habits, and advancements in healthcare infrastructure development.

The non-alcoholic steatohepatitis (nash) market size is expected to see exponential growth in the next few years. It will grow to $14.53 billion in 2028 at a compound annual growth rate (CAGR) of 33.7%. Anticipated growth in the forecast period is driven by advancements in NASH drug development, increased screening initiatives, higher healthcare spending, collaborative research, and government support. Key trends include a focus on lifestyle interventions, enhanced collaboration in clinical research, regulatory advancements, and the integration of artificial intelligence in diagnosis and monitoring.

The escalating prevalence of obesity is fueling the demand for the non-alcoholic steatohepatitis (NASH) market. Obesity, characterized by abnormal or excessive fat accumulation, poses significant health concerns, representing body weight that exceeds healthy or standard levels for a person of a given height. The increasing incidence of non-alcoholic fatty liver disease, driven by the obesity pandemic, positions NASH as a potential leading cause of severe liver disease in the coming decades. This heightened risk underscores the growing need for NASH treatment and related pharmaceuticals. As reported in the COVID-19 and Obesity, The 2021 Atlas published by the World Obesity Federation in April 2021, over 60% of the US population was recorded as overweight. Furthermore, the report projected an expected increase in obesity rates to 44.2% for males and 44.4% for females in the US population by 2025. This data highlights the alarming rise in obesity cases, reinforcing the anticipated growth trajectory of the Non-Alcoholic Steatohepatitis (NASH) market as a consequence of the obesity epidemic.

The rising demographic of the geriatric population is a key driver fueling the demand for the non-alcoholic steatohepatitis (NASH) market. The geriatric population, representing individuals aged 65 and older, exhibits specific healthcare needs associated with aging. The ongoing development and advancements in treatments within the NASH market play a crucial role in enhancing overall health outcomes for the elderly, addressing a prevalent liver-related condition prevalent in aging individuals. As indicated by the World Health Organization in October 2022, the global elderly population is anticipated to witness a significant increase, with 1 in 6 individuals being 60 or older by 2030 and an estimated 2.1 billion elderly people by 2050. This demographic shift underscores the imperative role of the increasing geriatric population in driving the growth of the Non-Alcoholic Steatohepatitis (NASH) market.

Technological advancement is a pivotal trend gaining traction in the non-alcoholic steatohepatitis (NASH) market, with major players in the industry actively pursuing technological innovations to sustain their positions. An illustrative example is the initiative undertaken by GENFIT Inc., a France-based biotechnology company, in May 2021. GENFIT launched NASHnext, a novel non-invasive test designed for diagnosing non-alcoholic steatohepatitis (NASH). NASHnext leverages the power of NIS4TM, an exclusive screening technology developed by GENFIT, utilizing a groundbreaking blood-based molecular biomarker test for the detection of NASH and severe fibrosis. This advanced diagnostic test is currently available exclusively in the United States and Canada through Labcorp, a prominent global life sciences company. By integrating cutting-edge technology into diagnostic solutions, companies such as GENFIT aim to enhance the accuracy and efficiency of NASH diagnosis, reflecting the broader trend of technological innovation within the non-alcoholic steatohepatitis market.

Prominent companies in the non-alcoholic steatohepatitis (NASH) market are actively engaged in the development of innovative products, exemplified by a focus on a thyroid hormone receptor (THR)-B selective agonist. This innovative therapeutic approach is designed to target fundamental underlying causes of non-alcoholic steatohepatitis. The thyroid hormone receptor, a pivotal protein regulating gene expression upon binding with thyroid hormones, plays a crucial role in various physiological processes. A case in point is Madrigal Pharmaceuticals, Inc., a US-based clinical-stage biopharmaceutical company, which completed the submission of a New Drug Application in July 2023, seeking accelerated approval for Resmetirom in the treatment of NASH with liver fibrosis. Resmetirom, offering once-daily oral therapy and liver-directed action, specifically targets hepatic steatosis, inflammation, and hepatocellular injury associated with NASH and liver fibrosis. Notably designated as a Breakthrough Therapy by the FDA, and supported by a comprehensive clinical development program, including Phase 3 trials, Resmetirom showcases significant potential to address unmet medical needs. This advancement positions it as a promising addition to the evolving treatment landscape for NASH with liver fibrosis.

In July 2022, Advanz Pharma Corp. Limited, a prominent UK-based pharmaceutical company, successfully acquired Intercept Pharmaceuticals Inc for an undisclosed sum. This strategic acquisition is designed to solidify Advanz Pharma's position in the rare disease treatment sector, specifically through the addition of the ex-U.S. rights to Ocaliva (obeticholic acid), an orphan medicine used for treating primary biliary cholangitis (PBC). Intercept Pharmaceuticals Inc., a distinguished U.S.-based biopharmaceutical company specializing in innovative therapies for progressive non-viral liver disorders, aligns well with Advanz Pharma's strategic goals in expanding its pharmaceutical portfolio.

Major companies operating in the non-alcoholic steatohepatitis (nash) market report are NGM Biopharmaceuticals Inc., Novartis AG, AstraZeneca plc., GlaxoSmithKline plc., F. Hoffmann-La Roche AG, The Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Novo Nordisk A/S, Genfit SA, Cadila Pharmaceuticals Ltd., Intercept Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Blade Therapeutics Inc., Cempra Pharmaceuticals Inc., Galmed Pharmaceuticals Inc., Immuron Limited, Terns Pharmaceuticals Inc., Tobira Therapeutics Inc., Arena Pharmaceuticals Inc., Vivus LLC, Arisaph Pharmaceuticals Inc., Galectin Therapeutics Inc., Raptor Pharmaceutical Inc., VERVA Technologies Pvt. Ltd., Viking Therapeutics, Conatus Pharmaceuticals Inc., One Way Liver S.L., BioPredictive S.A.S., Madrigal Pharmaceuticals Inc., Cirius Therapeutics, Akero Therapeutics Inc., Echosens

North America was the largest region in the non alcoholic steatohepatitis (NASH) market share in 2023. The regions covered in the non-alcoholic steatohepatitis (nash) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the non-alcoholic steatohepatitis (nash) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-alcoholic steatohepatitis (NASH) market consists of sales of drugs that are used for the treatment of non-alcoholic fatty liver diseases. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Non-Alcoholic Steatohepatitis (NASH) Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on non-alcoholic steatohepatitis (nash) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for non-alcoholic steatohepatitis (nash) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The non-alcoholic steatohepatitis (nash) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Type: Solid; Liquid
• 2) By Product: Vitamin E and Pioglitazone; Ocaliva; Elafibranor; Selonsertib and Cenicriviroc; Other Products
• 3) By Disease Cause: Hypertension; Heart Disease; High Blood Lipid; Type 2 Diabetes; Obesity
• 4) By Sales Channel: Hospital Pharmacy; Retail Pharmacy; Online Provider
• 5) By Application: Oral; Parenteral
• Companies Mentioned: NGM Biopharmaceuticals Inc.; Novartis AG; AstraZeneca plc.; GlaxoSmithKline plc.; F. Hoffmann-La Roche AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Non-Alcoholic Steatohepatitis (NASH) Market Characteristics

3. Non-Alcoholic Steatohepatitis (NASH) Market Trends And Strategies

4. Non-Alcoholic Steatohepatitis (NASH) Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Non-Alcoholic Steatohepatitis (NASH) Market Size and Growth

• 5.1. Global Non-Alcoholic Steatohepatitis (NASH) Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Non-Alcoholic Steatohepatitis (NASH) Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Non-Alcoholic Steatohepatitis (NASH) Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Non-Alcoholic Steatohepatitis (NASH) Market Segmentation

• 6.1. Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Solid
• Liquid
• 6.2. Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Vitamin E and Pioglitazone
• Ocaliva
• Elafibranor
• Selonsertib and Cenicriviroc
• Other Products
• 6.3. Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hypertension
• Heart Disease
• High Blood Lipid
• Type 2 Diabetes
• Obesity
• 6.4. Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Provider
• 6.5. Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Oral
• Parenteral

7. Non-Alcoholic Steatohepatitis (NASH) Market Regional And Country Analysis

• 7.1. Global Non-Alcoholic Steatohepatitis (NASH) Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Non-Alcoholic Steatohepatitis (NASH) Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Market

• 8.1. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Non-Alcoholic Steatohepatitis (NASH) Market

• 9.1. China Non-Alcoholic Steatohepatitis (NASH) Market Overview
• 9.2. China Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Non-Alcoholic Steatohepatitis (NASH) Market

• 10.1. India Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Non-Alcoholic Steatohepatitis (NASH) Market

• 11.1. Japan Non-Alcoholic Steatohepatitis (NASH) Market Overview
• 11.2. Japan Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Non-Alcoholic Steatohepatitis (NASH) Market

• 12.1. Australia Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Non-Alcoholic Steatohepatitis (NASH) Market

• 13.1. Indonesia Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Non-Alcoholic Steatohepatitis (NASH) Market

• 14.1. South Korea Non-Alcoholic Steatohepatitis (NASH) Market Overview
• 14.2. South Korea Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Non-Alcoholic Steatohepatitis (NASH) Market

• 15.1. Western Europe Non-Alcoholic Steatohepatitis (NASH) Market Overview
• 15.2. Western Europe Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Non-Alcoholic Steatohepatitis (NASH) Market

• 16.1. UK Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Non-Alcoholic Steatohepatitis (NASH) Market

• 17.1. Germany Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Non-Alcoholic Steatohepatitis (NASH) Market

• 18.1. France Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Non-Alcoholic Steatohepatitis (NASH) Market

• 19.1. Italy Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Non-Alcoholic Steatohepatitis (NASH) Market

• 20.1. Spain Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Non-Alcoholic Steatohepatitis (NASH) Market

• 21.1. Eastern Europe Non-Alcoholic Steatohepatitis (NASH) Market Overview
• 21.2. Eastern Europe Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Non-Alcoholic Steatohepatitis (NASH) Market

• 22.1. Russia Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Non-Alcoholic Steatohepatitis (NASH) Market

• 23.1. North America Non-Alcoholic Steatohepatitis (NASH) Market Overview
• 23.2. North America Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Non-Alcoholic Steatohepatitis (NASH) Market

• 24.1. USA Non-Alcoholic Steatohepatitis (NASH) Market Overview
• 24.2. USA Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Non-Alcoholic Steatohepatitis (NASH) Market

• 25.1. Canada Non-Alcoholic Steatohepatitis (NASH) Market Overview
• 25.2. Canada Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Non-Alcoholic Steatohepatitis (NASH) Market

• 26.1. South America Non-Alcoholic Steatohepatitis (NASH) Market Overview
• 26.2. South America Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Non-Alcoholic Steatohepatitis (NASH) Market

• 27.1. Brazil Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Non-Alcoholic Steatohepatitis (NASH) Market

• 28.1. Middle East Non-Alcoholic Steatohepatitis (NASH) Market Overview
• 28.2. Middle East Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Non-Alcoholic Steatohepatitis (NASH) Market

• 29.1. Africa Non-Alcoholic Steatohepatitis (NASH) Market Overview
• 29.2. Africa Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Non-Alcoholic Steatohepatitis (NASH) Market Competitive Landscape And Company Profiles

• 30.1. Non-Alcoholic Steatohepatitis (NASH) Market Competitive Landscape
• 30.2. Non-Alcoholic Steatohepatitis (NASH) Market Company Profiles
  • 30.2.1. NGM Biopharmaceuticals Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Novartis AG
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. AstraZeneca plc.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. GlaxoSmithKline plc.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. F. Hoffmann-La Roche AG
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Non-Alcoholic Steatohepatitis (NASH) Market Other Major And Innovative Companies

• 31.1. The Takeda Pharmaceutical Company Limited
• 31.2. Gilead Sciences Inc.
• 31.3. Novo Nordisk A/S
• 31.4. Genfit SA
• 31.5. Cadila Pharmaceuticals Ltd.
• 31.6. Intercept Pharmaceuticals Inc.
• 31.7. Enanta Pharmaceuticals Inc.
• 31.8. Blade Therapeutics Inc.
• 31.9. Cempra Pharmaceuticals Inc.
• 31.10. Galmed Pharmaceuticals Inc.
• 31.11. Immuron Limited
• 31.12. Terns Pharmaceuticals Inc.
• 31.13. Tobira Therapeutics Inc.
• 31.14. Arena Pharmaceuticals Inc.
• 31.15. Vivus LLC

32. Global Non-Alcoholic Steatohepatitis (NASH) Market Competitive Benchmarking

33. Global Non-Alcoholic Steatohepatitis (NASH) Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Non-Alcoholic Steatohepatitis (NASH) Market

35. Non-Alcoholic Steatohepatitis (NASH) Market Future Outlook and Potential Analysis

• 35.1 Non-Alcoholic Steatohepatitis (NASH) Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Non-Alcoholic Steatohepatitis (NASH) Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Non-Alcoholic Steatohepatitis (NASH) Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer